Growth Hormone Secretagogues Drive GH, PRL, and ACTH Release via Distinct Age- and Gender-Dependent Mechanisms
Background
Growth hormone deficiency and age-related decline in GH secretion represent significant clinical challenges, yet existing tools like GHRH provide incomplete stimulation of the GH-axis. GHS — both peptidyl and non-peptidyl synthetic molecules — emerged as potent alternatives that act through specific GHSR receptors at the pituitary and hypothalamus. Beyond GH, the hypothalamo-pituitary axis also governs prolactin and ACTH/cortisol secretion, pathways relevant to stress endocrinology and adrenal function. The discovery of peripheral GHS receptors, particularly cardiac receptors, has expanded interest beyond neuroendocrine applications, suggesting non-endocrine roles that standard-of-care GH therapies do not address.
Study Design
A comprehensive review of human endocrine and non-endocrine activities of growth hormone secretagogues was conducted. The analysis examined dose-dependent GH-releasing effects, co-administration with GHRH, and differential responses across age groups and genders. Neuroendocrine endpoints included GH, prolactin (PRL), and ACTH/cortisol secretion. Peripheral receptor distribution — including cardiac tissue — was also evaluated. Studies referenced encompassed both peptidyl and non-peptidyl GHS compounds administered to human subjects, with mechanistic comparisons to CRH and AVP for ACTH-releasing activity.
Results
GHS produced strong, dose-dependent, and reproducible GH release acting primarily at the hypothalamic level, likely via stimulation of GHRH-secreting neurons and/or functional antagonism of somatostatin. GHS released more GH than GHRH alone, and co-administration of GHS with GHRH produced a synergistic GH response, contingent on an intact hypothalamo-pituitary unit. GH-releasing effects were gender-independent but showed marked age-related variation reflecting changes in neural control of anterior pituitary function. PRL-releasing activity was slight, direct, pituitary-level, and independent of both age and gender.
The acute ACTH/cortisol-stimulating effect of GHS was comparable to that of CRH and AVP, yet in physiological conditions it operated through central mechanisms at least partially independent of both, likely involving
GABAergicpathways — and showed a trend toward increase with ageing.
Cardiac receptors were found to be specific for peptidyl GHS and are proposed to mediate GH-independent cardiotropic activities in both animals and humans.
Key Findings
- GHS release more GH than GHRH alone; co-administration with GHRH produces a synergistic GH response.
- GH-releasing effect is gender-independent with marked age-related variation.
- ACTH/cortisol response to GHS is comparable to CRH and AVP, involves GABAergic mechanisms, and trends upward with ageing.
- PRL-releasing activity is slight, direct pituitary-level action, and independent of age and gender.
- Cardiac GHS receptors are specific to peptidyl GHS and mediate GH-independent cardiotropic effects in humans and animals.
Why It Matters
Clinicians and peptide users combining GHS with GHRH analogs (e.g., sermorelin or CJC-1295) should note the synergistic GH release depends entirely on hypothalamo-pituitary integrity — individuals with hypothalamic damage may not respond. The age-related increase in ACTH responsiveness to GHS is a practical safety flag: older users may experience disproportionate cortisol elevation, warranting monitoring. The cardiac-specific receptor profile of peptidyl GHS — independent of GH — opens a mechanistic rationale for cardioprotective research but also signals that peptidyl and non-peptidyl GHS are not interchangeable in cardiac contexts. MK-677 (ibutamoren) as a non-peptidyl GHS may not engage cardiac receptors the way peptidyl compounds do, a distinction critical for protocol design.
